Skip to content

Comparison of Procalcitonin Level in Normal Population and in Chronic Kidney Disease Patients Who Don't Have Infection

Comparison of Procalcitonin Level in Normal Population and in Chronic Kidney Disease Patients Who Don't Have Infection

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05585970
Enrollment
50
Registered
2022-10-19
Start date
2022-11-01
Completion date
2023-05-01
Last updated
2022-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease Patients Who Don't Have Infection

Brief summary

Chronic kidney disease (CKD) is a life threatening condition with high risk of pre-term death and need for dialysis. It is defined as kidney damage that has continued for more than 3 months as characterized by structural or functional abnormalities of the kidney, with or without decreased glomerular filtration rate (GFR). It is also defined as GFR \< 60mL/min/1.73 m2 for more than 3 months, with or without structural kidney damage. The PCT level in healthy individual without infection is below the limit of detection (0.01 ng/mL), and it is significantly elevated under the stimulation of pathogens. However, due to the pre-existing endogenous inflammation that occurs in CKD patients and the impaired kidney clearance, the reference range that applies to the general population may not be appropriate for diagnosing infections in CKD patients. More recently, debate has continued regarding whether the PCT level is increased in CKD patients without infection, and the optimal reference for CKD patients remains undetermined

Interventions

DIAGNOSTIC_TESTprocalcitonin

The PCT level in healthy individual without infection is below the limit of detection (0.01 ng/mL), and it is significantly elevated under the stimulation of pathogens

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
40 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Chronic Kidney Disease patients. * ESRD patients

Exclusion criteria

Any condition of infection or sepsis such as : * Fever * Increased TLC above normal * Tachycardia * Tachypnea * Disturbed conscious level

Design outcomes

Primary

MeasureTime frame
procalcitonin Level6 months

Countries

Egypt

Contacts

Primary ContactRofyda S Gadallah, resident doctor
rofaydahsaad@med.sohag.edu.eg01026015355
Backup ContactElham O Hamd, professor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026